Enzyme-catalyzed reactions have begun to transform pharmaceutical manufacturing, offering levels of selectivity and tunability that can dramatically improve chemical synthesis. Combining enzymatic reactions into multistep biocatalytic cascades brings additional benefits. Cascades avoid the waste generated by purification of intermediates. They also allow reactions to be linked together to overcome an unfavorable equilibrium or avoid the accumulation of unstable or inhibitory intermediates. We report an in vitro biocatalytic cascade synthesis of the investigational HIV treatment islatravir. Five enzymes were engineered through directed evolution to act on non-natural substrates. These were combined with four auxiliary enzymes to construct islatravir from simple building blocks in a three-step biocatalytic cascade. The overall synthesis requires fewer than half the number of steps of the previously reported routes.

No abstract

Carbonic anhydrase (CA) is one of nature's fastest enzymes and can dramatically improve the economics of carbon capture under demanding environments such as coal-fired power plants. The use of CA to accelerate carbon capture is limited by the enzyme's sensitivity to the harsh process conditions. Using directed evolution, the properties of a β-class CA from Desulfovibrio vulgaris were dramatically enhanced. Iterative rounds of library design, library generation, and high-throughput screening identified highly stable CA variants that tolerate temperatures of up to 107°C in the presence of 4.2 M alkaline amine solvent at pH >10.0. This increase in thermostability and alkali tolerance translates to a 4,000,000-fold improvement over the natural enzyme. At pilot scale, the evolved catalyst enhanced the rate of CO 2 absorption 25-fold compared with the noncatalyzed reaction.carbonic anhydrase | directed evolution | carbon capture R eleasing over 9 billion metric tons of CO 2 worldwide each year, coal-fired power plants are the leading anthropogenic source of CO 2 emission. A potential solution to reduce the release of CO 2 into the atmosphere is the implementation of carbon capture and sequestration (CCS) technology on coal-and natural-gas-fired power plants. Currently, one of the most viable postcombustion CCS technology options uses an amine solvent to remove CO 2 from the flue gas (1). Unfortunately, the large amount of energy required to release the CO 2 and regenerate the solvent would significantly increase the cost of electricity generated (2). The ideal solvent capture process uses a solvent such as an aqueous amine with fast CO 2 absorption kinetics and a low heat of desorption to minimize the solvent regeneration energy. However, a high rate of CO 2 absorption kinetics for an amine solvent correlates with a higher temperature of desorption, whereas solvents with low heat of desorption tend to have much slower adsorption kinetics (3, 4).With reaction rates approaching the limits of diffusion, carbonic anhydrase (CA) is one of the fastest enzymes known. The active site of CAs can turnover CO 2 and water to bicarbonate and a proton up to a million times per second, and are used by almost every living organism to maintain pH balance and transport carbon dioxide. It has been shown that CAs can be used to accelerate the capture of CO 2 (5) by serving as a catalyst in alkaline capture solvents with slow absorption kinetics (6, 7). The potential improvements of CAs on CCS process economics stems from several considerations. The faster absorption and desorption kinetics allows for smaller processing equipment with reduced capital and operating costs (6). The improved kinetics also allows the use of lower temperature capture and solvent regeneration process conditions, and decreases energy losses in the capture process. Another benefit is the improved range of solvent candidates with attractive thermochemical stability (e.g., low vapor pressure, low formation of heat stable salts, etc.), but otherwise unacceptable unca...

A KetoREDuctase (KRED) engineered via directed evolution technologies catalyzed the asymmetric reduction of (E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-oxopropyl)benzoate to the corresponding (S)-alcohol, a key intermediate in the synthesis of montelukast sodium (Singulair). Through synergistic efforts in process chemistry, molecular biology, bioinformatics and high throughput screening, a KRED with very high enantioselectivity (>99.9% ee) was developed for an economical and simple process that takes advantage of the physical properties of the substrate and product. The evolved KRED is an efficient and robust enzyme for catalyzing the reaction of an essentially water insoluble substrate (c log P ≈ 7) at a 100 g/L loading in the presence of ∼70% organic solvents at 45 °C. The biocatalytic process currently runs at >200 kg scale.

RNA molecules play diverse functional roles in natural biological systems. There has been growing interest in designing synthetic RNA counterparts for programming biological function. The design of synthetic RNA molecules that exhibit diverse activities, including sensing, regulatory, information processing, and scaffolding activities, has highlighted the advantages of RNA as a programmable design substrate. Recent advances in implementing these engineered RNA molecules as key control elements in synthetic genetic networks are highlighting the functional relevance of this class of synthetic elements in programming cellular behaviors.